AAPP 2027 Annual Meeting: Program & Speakers

24 sessions across 4 days with 32 confirmed speakers — the program for AAPP 2027 Annual Meeting, April 4–7, 2027 in Louisville, KY. From the official program; excludes exhibits and social events.

Featured speakers: Jeffrey R. Bishop · Randye Kaye · Ambrose Wong · JoAn R. Laes · Robert "Cole" Pueringer · Dana Chiulli · Richard Silvia · Caitlin McCoyd · Lacey J. Vann · Bob Haight · Amy Werremeyer · Austin Campbell · and 20 more below

Looking for dates, CME credits, pricing, or registration deadlines? They're on the main AAPP 2027 Annual Meeting page. For every poster and workshop, see the full official program.

April 4, 2027

April 5, 2027

  • 08:00–09:00LectureClinical Application SeriesMental Health Care in Oncology: Highlighting a Lived Experience

    Kelly N. Gable

    A session drawing on a patient's lived experience and current evidence to examine anxiety, depression and distress in people with cancer. It covers barriers to integrated mental health care and the psychiatric pharmacist's role in supporting patients, including menopause related to cancer treatment.

    Anxiety DisordersCollaborative & Integrated CareDepressionMedical Comorbidity & C-L Psychiatry

  • 09:15–10:15LectureWhen Panic Persists: Navigating Difficult to Treat Panic Disorder

    Sarah T. Thomason

    Reviews pharmacologic and nonpharmacologic options for panic disorder that persists after first-line treatment, including emerging strategies and how to apply evidence to complex cases. Covers monitoring treatment response and safety.

    Anxiety DisordersPharmacogenomics & Precision PsychiatryTreatment-Resistant Depression

  • 12:20–13:20LectureClinical Application SeriesMedication Strategies for Behavioral and Psychological Symptoms of Dementia

    Monica Mathys

    Reviews how behavioral and psychological symptoms of dementia present and weighs the evidence, benefits and risks of current and newly approved medications, including for Parkinson disease psychosis. Focuses on building individualized treatment plans.

    Antipsychotic PrescribingDementia & Cognitive DisordersGeriatric

  • 12:20–13:20LectureClinical Application SeriesImproving Psychotropic Prescribing in Foster Care: The Essential Role of the BCPP

    Danielle L. Stutzman

    Looks at why youth in foster care often receive complex psychotropic regimens and how board-certified psychiatric pharmacists can support safer prescribing. Covers stewardship approaches, barriers to including pharmacists on foster care teams, and state advocacy efforts.

    Child & AdolescentCollaborative & Integrated CareDeprescribing & PolypharmacyPractice, Policy & Workforce

  • 13:30–14:30LectureClinical Application SeriesMastering Mood Stabilizers: Navigating Interactions and Adverse Effects

    Charles F. Caley

    An online course on safe use of mood stabilizers, covering clinically important drug interactions, adverse effects, monitoring plans, and patient-centered counseling to support adherence and shared decision-making.

    Bipolar DisorderDrug Interactions & SafetyLithium & Mood Stabilizers

  • 13:30–14:30LectureMember-Submitted ProgramNavigating Difficult Conversations in Psychiatric Pharmacy: Practical Strategies for Learners, Preceptors, and Leaders

    Maria Blaze

    An online course on preparing for and handling high-stakes conversations with patients, learners, and colleagues in psychiatric pharmacy practice. It covers separating facts from assumptions, building psychological safety, and using structured communication techniques.

    Education & TrainingPractice, Policy & Workforce

  • 14:50–15:50LectureMember-Submitted ProgramAntipsychotic Pharmacogenomics: Consensus Guideline Updates and Clinical Application

    Jeffrey R. Bishop

    Reviews current consensus guidelines on pharmacogenomic testing for antipsychotic therapy, key gene-drug interactions, and which patients may benefit most. Uses real-world clinical scenarios to show how to apply results to treatment decisions.

    Antipsychotic PrescribingPharmacogenomics & Precision PsychiatrySchizophrenia & Psychosis

  • 14:50–15:50LectureClinical Application SeriesNeuropsychiatric Comorbidities of Multiple Sclerosis

    Michelle Rainka

    Covers how common psychiatric symptoms present in people with multiple sclerosis and reviews the safety and efficacy of pharmacologic options given limited evidence. Focuses on choosing individualized treatment regimens for co-occurring psychiatric symptoms.

    Drug Interactions & SafetyMedical Comorbidity & C-L Psychiatry

April 6, 2027

April 7, 2027

Program details verified November 4, 2026; sessions and speakers may change — confirm on the official site.

Browse the directory

Recurring meetings